Niels van de Donk

DR., (Principal Investigator)

20122019
If you made any changes in Pure these will be visible here soon.

Research Output 2012 2019

Filter
Comment/Letter to the editor
2019

CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia

Naik, J., Themeli, M., de Jong-Korlaar, R., Ruiter, R. W. J., Poddighe, P. J., Yuan, H., de Bruijn, J. D., Ossenkoppele, G. J., Zweegman, S., Smit, L., Mutis, T., Martens, A. C. M., van de Donk, N. W. C. J. & Groen, R. W. J., 2019, In : Haematologica. 104, 3, p. e100-e103

Research output: Contribution to journalComment/Letter to the editorAcademic

Open Access

Oral proteasome inhibitor maintenance for multiple myeloma

van de Donk, N. W. C. J. & Yong, K., 2019, In : The Lancet. 393, 10168, p. 204-205

Research output: Contribution to journalComment/Letter to the editorAcademic

2017

Carfilzomib versus bortezomib: no longer an ENDEAVOR

van de Donk, N. WCJ., 1 Oct 2017, In : The Lancet Oncology. 18, 10, p. 1288-1290 3 p.

Research output: Contribution to journalComment/Letter to the editorAcademic